|
Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors
RECRUITINGPhase 4Sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital
Actively Recruiting
PhasePhase 4
SponsorKaohsiung Medical University Chung-Ho Memorial Hospital
Started2022-04-26
Est. completion2026-12-31
Eligibility
Age20 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05331911
Summary
This is a two-arm, parallel-group randomized clinical trial. Routine perioperative care would be performed in volunteers with primary Hepatocellular carcinoma. The study will enroll approximately 500 volunteers to compare the progression-free or overall survival in patients undergoing elective partial hepatectomy for primary liver tumors between propofol and sevoflurane for the maintenance of anesthesia.
Eligibility
Age: 20 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Twenty to eighty-year-old. 2. ASA class I-III. 3. Patients undergoing partial hepatectomy for hepatocellular carcinoma under general anesthesia. Exclusion Criteria: 1. Severe mental disorder 2. Pregnant or lactating women 3. Morbidly obese 4. Allergy to any of the drugs used in this study 5. Recurrent tumor or repeat surgery 6. Biopsy cases 7. Incomplete data collection before the surgery 8. Palliative treatment after surgery 9. simultaneous treatment of other malignancies 10. Combined propofol and inhalation anesthesia or other anesthetics, such as ketamine or dexmedetomidine 11. Diagnosed as benign liver tumor 12. Emergency surgery
Conditions4
CancerHepatocellular CarcinomaLiver CancerLiver Disease
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 4
SponsorKaohsiung Medical University Chung-Ho Memorial Hospital
Started2022-04-26
Est. completion2026-12-31
Eligibility
Age20 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05331911